Plant Compound PCC1 Fights Aging Skin Fibrosis by Blocking a Key Growth Receptor
Procyanidin C1, a natural polyphenol, reduces aging-related skin scarring by targeting EGFR and shutting down fibrosis signaling pathways.
Summary
Researchers found that Procyanidin C1 (PCC1), a natural compound from plants with known senolytic properties, can reduce aging-related skin fibrosis by directly binding to the epidermal growth factor receptor (EGFR) and blocking its activation. This suppresses downstream fibrosis-promoting pathways including TGFβ/SMAD, ERK/MAPK, and AKT/mTOR. In aged cell models and bleomycin-treated mice, PCC1 reduced senescence markers, improved collagen structure, and restored healthier skin architecture. These findings position PCC1 as a promising natural therapeutic candidate for a condition that currently has very limited treatment options.
Detailed Summary
Aging-related skin fibrosis is characterized by excessive collagen accumulation, loss of skin elasticity, and chronic inflammation driven by senescent cells. Current treatments remain limited, making novel therapeutic approaches critically important for an aging global population.
This study investigated Procyanidin C1 (PCC1), a polyphenolic compound found in grape seeds and certain berries, which has previously demonstrated the ability to selectively clear senescent cells. Researchers used D-galactose-induced aging in L929 fibroblast cells and bleomycin-induced fibrosis in mice to model the condition, combining network pharmacology, molecular docking, and multiple binding assays to identify PCC1's primary molecular target.
PCC1 significantly reduced expression of senescence markers (IL-1β, P16, P21, LMNB1) and fibrosis markers (α-SMA, LOXL2, COL1) in aged fibroblasts. Through rigorous target identification methods including DARTS, CETSA, and microscale thermophoresis, EGFR was confirmed as the direct binding partner. PCC1 blocked EGFR phosphorylation and consequently suppressed TGFβ1 expression and SMAD2/3 activation, as well as ERK/MAPK and AKT/mTOR signaling cascades.
In the mouse model, PCC1 reduced epidermal hyperplasia, restored the collagen I/III ratio toward healthier proportions, and diminished fibrotic signaling at the tissue level. The dual mechanism — clearing senescent cells while directly inhibiting EGFR — distinguishes PCC1 from single-target approaches.
While these results are encouraging, the study is limited to preclinical models. Translation to human skin aging and fibrotic disease requires clinical trials. Bioavailability and optimal dosing of PCC1 in humans also remain to be established before therapeutic application is feasible.
Key Findings
- PCC1 directly binds and inhibits EGFR phosphorylation, confirmed via molecular docking, DARTS, CETSA, and MST assays.
- Senescence markers IL-1β, P16, P21, and LMNB1 were significantly reduced in D-galactose-aged fibroblasts treated with PCC1.
- PCC1 suppressed TGFβ/SMAD, ERK/MAPK, and AKT/mTOR signaling pathways simultaneously.
- In bleomycin-induced fibrotic mice, PCC1 restored collagen I/III ratio and reduced epidermal hyperplasia.
- PCC1 works through dual mechanisms: senolytic activity and direct modulation of fibroblast fibrotic signaling.
Methodology
The study used D-galactose-induced aging in L929 murine fibroblasts and bleomycin-induced skin fibrosis in mice as experimental models. Target identification employed network pharmacology combined with molecular docking and biophysical binding assays (DARTS, CETSA, MST). Both in vitro and in vivo endpoints assessed senescence, fibrosis markers, and signaling pathway activation.
Study Limitations
All findings are preclinical, relying on cell culture and mouse models that may not fully recapitulate human aging-related skin fibrosis. The bioavailability, optimal dosing, and long-term safety profile of PCC1 in humans have not been established. The study did not include human tissue validation or comparison with existing anti-fibrotic treatments.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.